659729-80-3

Usage

Uses

Used in Pharmaceutical Industry:
2(1H)-Quinoxalinone,3-amino-8-hydroxy-(9CI) serves as a key building block for the synthesis of various bioactive molecules. Its unique structure allows for the development of potential drugs and therapeutic agents that can target a range of health conditions.
Used in Research and Development:
As a compound with potential antioxidant and anti-inflammatory properties, 2(1H)-Quinoxalinone,3-amino-8-hydroxy-(9CI) is utilized in research and development efforts to explore its full spectrum of biological activities and therapeutic potential. Further investigation may lead to its application in the creation of novel treatments and medications.

InChI:InChI=1/C8H7N3O2/c9-7-8(13)11-6-4(10-7)2-1-3-5(6)12/h1-3,12H,(H2,9,10)(H,11,13)

Upstream product

• 659729-78-9 3-amino-8-methoxy-1H-quinoxalin-2-one 

Relevant academic research and scientific papers

Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate

A series of novel 4-oxopyrimidine TRPV1 antagonists was evaluated in assays measuring the blockade of capsaicin or acid-induced influx of calcium into CHO cells expressing TRPV1. The investigation of the structure-activity relationships in the heterocyclic A-region revealed the optimum pharmacophoric elements required for activity in this series and resulted in the identification of subnanomolar TRPV1 antagonists. The most potent of these antagonists were thoroughly profiled in pharmacokinetic assays. Optimization of the heterocyclic A-region led to the design and synthesis of 23, a compound that potently blocked multiple modes of TRPV1 activation. Compound 23 was shown to be effective in a rodent "on-target" biochemical challenge model (capsaicin-induced flinch, ED50 = 0.33 mg/kg p.o.) and was antihyperalgesic in a model of inflammatory pain (CFA-induced thermal hyperalgesia, MED = 0.83 mg/kg, p.o.). Based on its in vivo efficacy and pharmacokinetic profile, compound 23 (N-{4-[6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-benzothiazol-2-yl} -acetamide; AMG 517) was selected for further evaluation in human clinical trials.